Last edition
News about "Clinical Trial Notification "
Antengene Advances ATG-201 Autoimmune Programme with Australian Phase I Trial Approval
Antengene’s ATG-201 moves into multinational clinical development after receiving Australian ethics approval and completing the TGA’s CTN process for a Phase I study targeting B cell-related autoimmune diseases.
Clinical Trial Notification | 26/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members